Clincosm LogoSign in Get a demo

IReC-Bio Protocol for The International Centre for Recurrent Head and Neck Cancer (IReC) Clinical and Biological Tissue Bank

Sponsor
Royal Marsden NHS Foundation Trust (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05885490
Collaborator
(none)
10,000,000
Enrollment
329
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

IReC is the world's first centre for recurrent head and neck cancers. We have the ambitious aim to create a centre of international excellence and set international standards in the curative treatment of recurrent head and neck cancers.

One of IReC's key objectives is to develop a national research tissue bank to support laboratory and translational research. The cornerstone of translational research is a well-annotated biobank of cancer samples to explore and validate key research findings.

The purpose of IReC-Bio is to support research into recurrent head and neck cancers. A central repository for the rarer recurrent cancers will allow the concentration of cases required in order to support translational research programmes. The overall aim is to facilitate research into understanding disease biology, identifying potentially curative treatments, and allow detailed investigations into the relationships between clinical, pathological and molecular characteristics and clinical outcomes.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    10000000 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Protocol for The International Centre for Recurrent Head and Neck Cancer (IReC) Clinical and Biological Tissue Bank
    Anticipated Study Start Date :
    Jul 1, 2023
    Anticipated Primary Completion Date :
    Dec 1, 2050
    Anticipated Study Completion Date :
    Dec 1, 2050

    Arms and Interventions

    Arm Intervention/Treatment
    Group 1

    Patients undergoing treatment for histologically proven or suspected recurrent cancer of the head and neck

    Outcome Measures

    Primary Outcome Measures

    1. Development of a national research tissue bank [Up to 50 years]

      Development of a national research tissue bank - collection of samples collected from patients with H&N cancer to be used in future approved research. Outcome will be measured by collection of samples from eligible participants for use in future research. Samples collected will be stored within the Royal Marsden Biobank.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Proven or suspected of recurrent cancers of the head and neck

    • FFPE blocks(s) or fresh frozen tumour tissue available for collection

    • Details of clinical follow-up available

    • Two or more tumour-containing blocks available from the same specimen

    Exclusion Criteria:

    • FFPE tumour samples contain insufficient tumour sample for analysis

    • Insufficient clinical details available

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Royal Marsden NHS Foundation Trust

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Royal Marsden NHS Foundation Trust
    ClinicalTrials.gov Identifier:
    NCT05885490
    Other Study ID Numbers:
    • 5604
    First Posted:
    Jun 2, 2023
    Last Update Posted:
    Jun 2, 2023
    Last Verified:
    May 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Head and Neck Neoplasms

    Study Results

    No Results Posted as of Jun 2, 2023